Novel imaging agent allows for earlier detection of progressive pulmonary fibrosis

Reston, VA—A newly developed PET imaging agent, ⁶⁴Cu-GPVI-Fc, can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner. This research was published in the June issue of The Journal of Nuclear Medicine.

Pulmonary fibrosis is a fatal disease with a life expectancy of three to five years after diagnosis. While it is relatively easy to diagnose in its advanced stages, it is difficult to identify pulmonary fibrosis is its earliest stages when treatment of the disease is most effective.

“Currently, routine clinical diagnosis of pulmonary fibrosis relies on breathing tests and visualizing the changes in lung structure with CT, but this anatomical information is often not sufficient to identify early signs of the disease,” said Nicolas Bézière, PhD, head of Imaging of Infection and Inflammation at the Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy at Eberhard Karls University of Tübingen in Tübingen, Germany. “Molecular imaging of the biomarkers of pulmonary fibrosis could lead to earlier detection and better monitoring, as well as provide a novel way to assess treatment efficacy.”

In patients with pulmonary fibrosis, remodeling of lung tissue occurs through increased deposition of extracellular matrix fibers, such as collagen I-III, fibronectin and fibrinogen. In the study, researchers used ⁶⁴Cu-GPVI-Fc, an imaging agent that targets these extracellular matrix fibers, to identify pulmonary fibrosis in a mouse model. These results were compared to histological findings, as well as to imaging with ¹⁸F-FDG PET.

⁶⁴Cu-GPVI-Fc showed significant uptake in lungs with pulmonary fibrosis, which matched histological results. Contrary to the findings of the ¹⁸F-FGD PET imaging, ⁶⁴Cu-GPVI-Fc uptake was entirely linked to pulmonary fibrosis activity in the lung tissues and did not identify any inflammation.

“In a disease with such a large impact on the patients’ quality of life and with such a reduced life expectancy after diagnosis, it is critical that proper diagnosis and treatment follow-up methods are specific and sensitive enough that optimal medical care can be given. We believe ⁶⁴Cu-GPVI-Fc takes us one step closer to personalized medicine for pulmonary fibrosis,” noted Bézière.

He continued, “We hope that this approach based on a tracer targeting a range of extracellular matrix fibers will provide a new way to view the ‘complete picture’ of pulmonary fibrosis progression and act as a new method to monitor treatment efficacy. Furthermore, fibrosis is not limited to the lungs, it can develop in other organs and lead to a loss of their function. Thus, we can foresee the transfer of this approach to other fibrotic diseases.”

The authors of “Radiolabeled GPVI-Fc for PET imaging of multiple extracellular matrix fibers: A new look into pulmonary fibrosis progression” include Simon Isser, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Germany; Andreas Maurer, Gerlad Reischl, and Bernd J. Pichler, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Germany, and Cluster of Excellence EXC 2180 "Image Guided and Functionally Instructed Tumor Therapies" (iFIT), Eberhard Karls University of Tübingen, Germany; Martin Schaller, Department of Dermatology, University Medical Center, Eberhard Karls University of Tübingen, Germany; Irene Gonzalez-Menendez and Leticia Quintanilla-Martinez, Cluster of Excellence EXC 2180 "Image Guided and Functionally Instructed Tumor Therapies" (iFIT), Eberhard Karls University of Tübingen, Germany, and Institute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard Karls University of Tübingen, Germany; Meinrad Gawaz, Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Germany; and Nicolas Bézière, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Germany, and Cluster of Excellence EXC 2124 “Controlling Microbes to Fight Infections” (CMFI), Eberhard Karls University of Tübingen, Germany.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.